A share price of Akero Therapeutics Inc [AKRO] is currently trading at $54.52, down -0.35%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AKRO shares have gain 5.64% over the last week, with a monthly amount glided 36.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.02 and $58.40. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $54.52 at the most recent close of the market. An investor can expect a potential drop of -15.63% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.32 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 16.80. Also, the Quick Ratio is 16.80, while the Cash Ratio stands at 4.38.
Transactions by insiders
Recent insider trading involved Rolph Timothy, Chief Scientific Officer, that happened on Jun 06 ’25 when 25000.0 shares were sold. Chief Scientific Officer, Rolph Timothy completed a deal on Jun 05 ’25 to sell 12500.0 shares. Meanwhile, Senior VP, Commercial Strategy Lamy Patrick sold 4000.0 shares on Jun 02 ’25.
